Effects of Vonoprazan combined with standard quadruple therapy in treatment of Hp positive gastroesophageal reflux disease
Objective:To observe effects of Vonoprazan combined with standard quadruple therapy in treatment of Helicobacter pylori(Hp)positive gastroesophageal reflux disease.Methods:A prospective study was conducted on 80 patients with Hp-positive gastroesophageal reflux disease admitted to this hospital from February 2021 to March 2023.According to the random number table method,they were divided into study group and control group,40 cases in each group.The control group was treated with standard quadruple therapy,while the study group was treated with Vonoprazan on the basis of that of the control group.The clinical efficacy,the Hp eradication rate,the esophageal sphincter resting pressure[upper esophageal sphincter(UES)resting pressure,lower esophageal sphincter(LES)resting pressure]levels,the gastrointestinal hormone index[pepsinogen I(PGI),gastrin-17(G-17)]levels,and the gastrointestinal mucosal barrier function index[diamine oxidase(DAO),D-lactic acid,endotoxin]levels were compared between the two groups before and after the treatment.Results:The total effective rate of treatment in the study group was 97.50%(39/40),which was higher than 77.50%(31/40)in the control group,and the difference was statistically significant(P<0.05).The eradication rate of Hp in the study group was 87.50%(35/40),which was higher than 67.50%(27/40)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the resting pressure levels of USE and LES in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of PGI and G-17 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of DAO,D-lactic acid and endotoxin in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Vonoprazan combined with standard quadruple therapy can improve the clinical efficacy,the Hp eradication rate,the esophageal sphincter resting pressure index levels,the gastrointestinal hormone index levels and the gastrointestinal mucosal barrier function index levels in the patients with Hp-positive gastroesophageal reflux disease.Moreover,it is superior to single standard quadruple therapy.
万方数据
维普
